Chaya Friedman

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.

V. Seshan, A. Zelenetz, O. Abdel-Wahab, 2021, The Lancet. Haematology.

Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)

V. Seshan, A. Zelenetz, O. Abdel-Wahab, 2021, Blood.